Phase III Trials: It’s crunch time for these ASX health stocks
Several ASX-listed companies are making significant strides in their phase III clinical trials, the critical final stage ...
Listed drug development sector has several promising stories to tell this year
It’s shaping up as a big year for late-stage Australian-listed drug developers, with analysts tipping potentially hefty share ...
Analysts Have Conflicting Sentiments on These Healthcare Companies: Nanosonics Limited (OtherNNCSF) and Eli Lilly & Co (LLY)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Nanosonics Limited (NNCSF – Research Report) and Eli Lilly ...
Wall Street Journal1d
Neuren Pharmaceuticals Ltd.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
The Weekly Times2d
Listed drug development sector has several promising stories to tell this year
Dr Storey said he also favoured Neuren Pharmaceuticals, with the share price having come under pressure recently, but he said it had “a terrific asset’’ which will come into its own over the ...